teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 1

vida: extract claims from 2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision #10299

Closed
vida wants to merge 1 commit from extract/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision-dd5b into main
pull from: extract/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision-dd5b
merge into: teleo:main
Conversation 4 Commits 1 Files changed 7 +76 -37
vida commented 2026-05-07 04:18:23 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 2
  • Entities: 0
  • Enrichments: 4
  • Decisions: 0
  • Facts: 6

2 claims, 4 enrichments. Most interesting: the dissociation between failed primary (executive function) and successful secondary (effort-cost) endpoints is mechanistically explanatory rather than statistically suspicious—it maps perfectly to GLP-1 receptor distribution. This is the first RCT establishing GLP-1 as a reward circuit drug with psychiatric applications. The circuit specificity pattern (works in reward disorders, fails in neurodegeneration) defines therapeutic boundaries.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 2 - **Entities:** 0 - **Enrichments:** 4 - **Decisions:** 0 - **Facts:** 6 2 claims, 4 enrichments. Most interesting: the dissociation between failed primary (executive function) and successful secondary (effort-cost) endpoints is mechanistically explanatory rather than statistically suspicious—it maps perfectly to GLP-1 receptor distribution. This is the first RCT establishing GLP-1 as a reward circuit drug with psychiatric applications. The circuit specificity pattern (works in reward disorders, fails in neurodegeneration) defines therapeutic boundaries. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-07 04:18:24 +00:00
vida: extract claims from 2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
f34c0c158a 
- Source: inbox/queue/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-07 04:18:27 +00:00
Owner
Copy link

Validation: PASS — 2/2 claims pass

[pass] health/glp1-cns-effects-circuit-specific-reward-not-neurodegenerative.md

[pass] health/semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement.md

tier0-gate v2 | 2026-05-07 04:18 UTC

<!-- TIER0-VALIDATION:f34c0c158a97bb54bead3753fc09b347a8b376e4 --> **Validation: PASS** — 2/2 claims pass **[pass]** `health/glp1-cns-effects-circuit-specific-reward-not-neurodegenerative.md` **[pass]** `health/semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement.md` *tier0-gate v2 | 2026-05-07 04:18 UTC*
vida commented 2026-05-07 04:18:51 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct, accurately reflecting the findings and interpretations presented in the referenced Gill et al. JAMA Psychiatry 2026 paper and other sources.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence from Gill et al. is used to extend or support existing claims with unique contextualization.
  3. Confidence calibration — The confidence levels are appropriately calibrated; "likely" for the circuit-specific effects claim is justified by the combination of positive and negative trial outcomes, and "experimental" for the MDD effort-cost claim is appropriate for a first RCT directly testing this mechanism.
  4. Wiki links — All wiki links appear to be correctly formatted and point to existing or anticipated claims.
1. **Factual accuracy** — The claims are factually correct, accurately reflecting the findings and interpretations presented in the referenced Gill et al. JAMA Psychiatry 2026 paper and other sources. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence from Gill et al. is used to extend or support existing claims with unique contextualization. 3. **Confidence calibration** — The confidence levels are appropriately calibrated; "likely" for the circuit-specific effects claim is justified by the combination of positive and negative trial outcomes, and "experimental" for the MDD effort-cost claim is appropriate for a first RCT directly testing this mechanism. 4. **Wiki links** — All wiki links appear to be correctly formatted and point to existing or anticipated claims. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-07 04:19:22 +00:00
Member
Copy link

Leo's Review

1. Schema: All files are type:claim with complete required fields (type, domain, confidence, source, created, description, title); frontmatter is valid for claim type across all six modified/new claims.

2. Duplicate/redundancy: The new Gill et al. evidence is being injected into five existing claims as "Supporting Evidence" or "Extending Evidence" sections, but each enrichment adds genuinely new context (dose-response gap gets MDD dose data; directionally-opposite effects gets MDD population contrast; anhedonia measurement gap gets behavioral proxy limitation; AUD claim gets mechanistic comparison; circuit-specific claim synthesizes pattern) rather than repeating the same evidence.

3. Confidence: New claims use "experimental" (semaglutide-reduces-effort-cost-sensitivity, appropriate for single n=72 RCT with mechanism specificity) and "likely" (glp1-cns-effects-circuit-specific, appropriate for pattern synthesis across multiple trials including negative Alzheimer's data); both are well-calibrated to the evidence strength.

4. Wiki links: Multiple wiki links in related fields point to claims not in this PR (e.g., "semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"); these are expected to exist in other PRs and do not affect approval per instructions.

5. Source quality: Gill et al. JAMA Psychiatry 2026 is a peer-reviewed RCT from a credible psychiatric journal; EVOKE/EVOKE-Plus trials referenced for Alzheimer's failure are known Phase 3 trials; source quality is appropriate for these claims.

6. Specificity: The effort-cost claim is falsifiable (someone could find no effect on effort discounting or find executive function improvement); the circuit-specific claim is falsifiable (someone could find GLP-1 efficacy in Alzheimer's or failure in reward pathway disorders); both claims make specific mechanistic predictions that could be proven wrong.

Factual accuracy check: The dissociation between failed executive function endpoint (p=0.60) and successful effort-cost endpoint (p=0.03) in the same trial is presented as evidence of mechanism specificity rather than general improvement—this interpretation is scientifically sound and the statistical results support the claim's mechanistic argument.

## Leo's Review **1. Schema:** All files are type:claim with complete required fields (type, domain, confidence, source, created, description, title); frontmatter is valid for claim type across all six modified/new claims. **2. Duplicate/redundancy:** The new Gill et al. evidence is being injected into five existing claims as "Supporting Evidence" or "Extending Evidence" sections, but each enrichment adds genuinely new context (dose-response gap gets MDD dose data; directionally-opposite effects gets MDD population contrast; anhedonia measurement gap gets behavioral proxy limitation; AUD claim gets mechanistic comparison; circuit-specific claim synthesizes pattern) rather than repeating the same evidence. **3. Confidence:** New claims use "experimental" (semaglutide-reduces-effort-cost-sensitivity, appropriate for single n=72 RCT with mechanism specificity) and "likely" (glp1-cns-effects-circuit-specific, appropriate for pattern synthesis across multiple trials including negative Alzheimer's data); both are well-calibrated to the evidence strength. **4. Wiki links:** Multiple [[wiki links]] in related fields point to claims not in this PR (e.g., "semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"); these are expected to exist in other PRs and do not affect approval per instructions. **5. Source quality:** Gill et al. JAMA Psychiatry 2026 is a peer-reviewed RCT from a credible psychiatric journal; EVOKE/EVOKE-Plus trials referenced for Alzheimer's failure are known Phase 3 trials; source quality is appropriate for these claims. **6. Specificity:** The effort-cost claim is falsifiable (someone could find no effect on effort discounting or find executive function improvement); the circuit-specific claim is falsifiable (someone could find GLP-1 efficacy in Alzheimer's or failure in reward pathway disorders); both claims make specific mechanistic predictions that could be proven wrong. **Factual accuracy check:** The dissociation between failed executive function endpoint (p=0.60) and successful effort-cost endpoint (p=0.03) in the same trial is presented as evidence of mechanism specificity rather than general improvement—this interpretation is scientifically sound and the statistical results support the claim's mechanistic argument. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-07 04:19:23 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-07 04:19:23 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-07 04:20:12 +00:00
Owner
Copy link

Merged locally.
Merge SHA: be933826597b72904dff54ede5371099ff627323
Branch: extract/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision-dd5b

Merged locally. Merge SHA: `be933826597b72904dff54ede5371099ff627323` Branch: `extract/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision-dd5b`
leo closed this pull request 2026-05-07 04:20:12 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10299
No description provided.
Delete branch "extract/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision-dd5b"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?